C-X-C chemokine receptor type 4 (CXCR4) and C-X-C motif chemokine 12 (CXCL12) axis (CXCR4-CXCL12)

The CXCR4–CXCL12 chemokine axis is a critical signaling pathway composed of the G protein-coupled receptor C-X-C chemokine receptor type 4 (CXCR4) and its primary ligand, the chemokine C-X-C motif chemokine 12 (CXCL12). This axis plays a fundamental role in regulating the trafficking and homing of hematopoietic stem cells (HSCs) within the bone marrow niche and the migration of immune cells during development and immune surveillance. In oncology, the axis is frequently hijacked; CXCR4 is overexpressed in numerous solid and hematological malignancies, where it promotes tumor cell survival, proliferation, angiogenesis, and organ-specific metastasis toward CXCL12-rich environments like the liver and lungs. Additionally, CXCR4 serves as a key co-receptor for the entry of X4-tropic HIV-1 into host T cells. Therapeutic strategies primarily focus on CXCR4 antagonists, such as plerixafor and mavorixafor, which are used to mobilize stem cells for transplantation or treat genetic disorders like WHIM syndrome. Ongoing research explores the potential of this axis to overcome chemoresistance and enhance the efficacy of immunotherapies by modulating the tumor microenvironment.

Other names

SDF-1/CXCR4 axisStromal cell-derived factor 1/CXCR4 axisCD184SDF-1LESTRFusinCXC-R4CXCL12-CXCR4 axis

The primary mechanism of action for drugs targeting this axis is the competitive antagonism of the CXCR4 receptor, which prevents the binding of its ligand CXCL12 and inhibits downstream signaling pathways such as PI3K/AKT and MAPK/ERK. Other approaches include the use of neutralizing agents that bind directly to the CXCL12 ligand to prevent its interaction with CXCR4 or the alternative receptor CXCR7.